Internal Medicine, Rheumatology · Alexandria, LA
NPI
1508859455
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
146 Yorktown Dr
Alexandria, LA, 71303
Phone (318) 416-5060
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.4M
97,829 services
Medicare patients, 2024
392
Average age 71
Drug cost, 2024
$7.0M
10,626 prescriptions
Company payments, 2025
$1,222
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Miguel A Garcia-Caro was code J1602 (injection, golimumab, 1 mg, for intravenous use), 44,100 times for 43 patients. In total Miguel A Garcia-Caro billed 97,829 services in 42 codes, and Medicare paid $1.4M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-10-10.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 44,100 | 43 | $8.86 | $391K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 12,500 | 16 | $33.85 | $423K |
| J0897 Injection, denosumab, 1 mg | Office | 2,460 | 23 | $20.41 | $50K |
| 99213 Office E&M - Established | Office | 1,396 | 375 | $62.66 | $87K |
| 96413 Chemotherapy Administration | Office | 630 | 86 | $93.38 | $59K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 372 | 75 | $0.74 | $273 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 171 | 128 | $12.65 | $2,163 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 165 | 33 | $4.12 | $679 |
| 99214 Office E&M - Established | Office | 138 | 88 | $97.16 | $13K |
| J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 100 | 18 | $5.27 | $527 |
| 96401 Chemotherapy Administration | Office | 94 | 29 | $53.14 | $4,995 |
| 96415 Chemotherapy Administration | Office | 77 | 11 | $20.82 | $1,603 |
| 20610 Joint Injection | Office | 75 | 56 | $47.97 | $3,597 |
| 99203 Office E&M - New | Office | 39 | 39 | $75.64 | $2,950 |
| 96365 Intravenous Infusion, Hydration | Office | 28 | 28 | $36.71 | $1,028 |
By year: 2022 $1.6M for 119,747 services; 2023 $1.7M for 116,679 services; 2024 $1.4M for 97,829 services.
Medicare prescription drug claims, 2024
In 2024, the drug Miguel A Garcia-Caro prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 942 prescriptions and refills. In total Miguel A Garcia-Caro wrote 10,626 Medicare prescriptions that cost $7.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 942 | 942 | 127 | $20K |
| Duloxetine Hcl Generic | 628 | 879 | 112 | $7,141 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 566 | 566 | 66 | $13K |
| Tramadol Hcl Generic | 427 | 454 | 85 | $4,592 |
| Gabapentin Generic | 398 | 516 | 78 | $4,080 |
| Prednisone Generic | 368 | 427 | 115 | $1,705 |
| Methotrexate Methotrexate Sodium | 320 | 526 | 76 | $3,230 |
| Pregabalin Generic | 311 | 368 | 55 | $4,682 |
| Hydroxychloroquine Sulfate Generic | 294 | 493 | 53 | $8,941 |
| Baclofen Generic | 264 | 357 | 64 | $3,247 |
| Meloxicam Generic | 208 | 263 | 43 | $805 |
| Tizanidine Hcl Generic | 203 | 285 | 39 | $2,911 |
| Levothyroxine Sodium Generic | 191 | 295 | 38 | $1,271 |
| Cyclobenzaprine Hcl Generic | 184 | 216 | 39 | $1,541 |
| Leflunomide Generic | 182 | 250 | 32 | $6,435 |
Brand drugs: 1,263 claims; generic drugs: 9,338 claims; opioid claims: 2,363.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Miguel A Garcia-Caro $1,222 ($1,222 in general payments such as food, travel and fees) from 11 companies. The largest payer was Amgen Inc. with $326.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 24 | $326 |
| ANI Pharmaceuticals, Inc. ANIP | 9 | $283 |
| Janssen Biotech, Inc. JNJ | 14 | $240 |
| Mallinckrodt Hospital Products Inc. | 5 | $103 |
| Galderma Laboratories, L.P. GALD.SW | 3 | $67.64 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $63.86 |
| UCB, Inc. UCB.BR | 2 | $33.59 |
| GlaxoSmithKline, LLC. GSK | 2 | $32.24 |
| Genentech USA, Inc. ROG.SW | 2 | $31.44 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $22.78 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.